Toxicity and efficacy of benzamide riboside in cancer chemotherapy models

Hiremagalur N. Jayaram, Joel A. Yalowitz, Francisco Arguello, John F. Greene

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Benzamide riboside (BR), a synthetic C-nucleoside, acts as a strong growth inhibitor of cancer cells in vitro and in vivo. BR, like TR and related nucleoside prodrugs, act by anabolism to NAD analogs. These analogs selectively inhibit IMPDH, leading to depletion of cellular GTP, growth cessation, and cell differentiation. To date only preclinical studies have been carried out. However, in tiazofurin (TR), a related drug, phase I/II clinical trials have been conducted in patients with acute leukemia and shown to be a very promising agent with a response rate of 85% in 26 patients in one of the trials. Tiazofurin is now undergoing phase III clinical trials as a result. Dose limiting toxicity of tiazofurin was headache, somnolence and nausea with no myelosuppression noted. By contrast, BR showed skeletal muscle toxicity, hepatotoxicity and myelosuppression in preclinical data. Skeletal muscle toxicity was noted in the paraspinal muscles and may represent dose-limiting toxicity. Since BR does exhibit myelosuppression, the most common chemotherapy-related side effect in humans, careful judgment is warranted should BR be included in multidrug regimens, although BR's potent cytotoxicity to tumor cells in preclinical models still makes it a promising drug.

Original languageEnglish (US)
Pages (from-to)787-792
Number of pages6
JournalCurrent Medicinal Chemistry
Volume9
Issue number7
StatePublished - 2002
Externally publishedYes

Fingerprint

tiazofurin
Chemotherapy
Toxicity
Drug Therapy
Muscle
Neoplasms
Nucleosides
Skeletal Muscle
Cells
Paraspinal Muscles
Growth Inhibitors
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Prodrugs
Cytotoxicity
Guanosine Triphosphate
Pharmaceutical Preparations
NAD
Nausea

Keywords

  • Apoptosis
  • Benzamide riboside
  • Cancer chemotherapy
  • Preclinical evaluation
  • Toxicity

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Jayaram, H. N., Yalowitz, J. A., Arguello, F., & Greene, J. F. (2002). Toxicity and efficacy of benzamide riboside in cancer chemotherapy models. Current Medicinal Chemistry, 9(7), 787-792.

Toxicity and efficacy of benzamide riboside in cancer chemotherapy models. / Jayaram, Hiremagalur N.; Yalowitz, Joel A.; Arguello, Francisco; Greene, John F.

In: Current Medicinal Chemistry, Vol. 9, No. 7, 2002, p. 787-792.

Research output: Contribution to journalArticle

Jayaram, HN, Yalowitz, JA, Arguello, F & Greene, JF 2002, 'Toxicity and efficacy of benzamide riboside in cancer chemotherapy models', Current Medicinal Chemistry, vol. 9, no. 7, pp. 787-792.
Jayaram HN, Yalowitz JA, Arguello F, Greene JF. Toxicity and efficacy of benzamide riboside in cancer chemotherapy models. Current Medicinal Chemistry. 2002;9(7):787-792.
Jayaram, Hiremagalur N. ; Yalowitz, Joel A. ; Arguello, Francisco ; Greene, John F. / Toxicity and efficacy of benzamide riboside in cancer chemotherapy models. In: Current Medicinal Chemistry. 2002 ; Vol. 9, No. 7. pp. 787-792.
@article{bafe40ca63584787b81a2bc729573c5e,
title = "Toxicity and efficacy of benzamide riboside in cancer chemotherapy models",
abstract = "Benzamide riboside (BR), a synthetic C-nucleoside, acts as a strong growth inhibitor of cancer cells in vitro and in vivo. BR, like TR and related nucleoside prodrugs, act by anabolism to NAD analogs. These analogs selectively inhibit IMPDH, leading to depletion of cellular GTP, growth cessation, and cell differentiation. To date only preclinical studies have been carried out. However, in tiazofurin (TR), a related drug, phase I/II clinical trials have been conducted in patients with acute leukemia and shown to be a very promising agent with a response rate of 85{\%} in 26 patients in one of the trials. Tiazofurin is now undergoing phase III clinical trials as a result. Dose limiting toxicity of tiazofurin was headache, somnolence and nausea with no myelosuppression noted. By contrast, BR showed skeletal muscle toxicity, hepatotoxicity and myelosuppression in preclinical data. Skeletal muscle toxicity was noted in the paraspinal muscles and may represent dose-limiting toxicity. Since BR does exhibit myelosuppression, the most common chemotherapy-related side effect in humans, careful judgment is warranted should BR be included in multidrug regimens, although BR's potent cytotoxicity to tumor cells in preclinical models still makes it a promising drug.",
keywords = "Apoptosis, Benzamide riboside, Cancer chemotherapy, Preclinical evaluation, Toxicity",
author = "Jayaram, {Hiremagalur N.} and Yalowitz, {Joel A.} and Francisco Arguello and Greene, {John F.}",
year = "2002",
language = "English (US)",
volume = "9",
pages = "787--792",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Toxicity and efficacy of benzamide riboside in cancer chemotherapy models

AU - Jayaram, Hiremagalur N.

AU - Yalowitz, Joel A.

AU - Arguello, Francisco

AU - Greene, John F.

PY - 2002

Y1 - 2002

N2 - Benzamide riboside (BR), a synthetic C-nucleoside, acts as a strong growth inhibitor of cancer cells in vitro and in vivo. BR, like TR and related nucleoside prodrugs, act by anabolism to NAD analogs. These analogs selectively inhibit IMPDH, leading to depletion of cellular GTP, growth cessation, and cell differentiation. To date only preclinical studies have been carried out. However, in tiazofurin (TR), a related drug, phase I/II clinical trials have been conducted in patients with acute leukemia and shown to be a very promising agent with a response rate of 85% in 26 patients in one of the trials. Tiazofurin is now undergoing phase III clinical trials as a result. Dose limiting toxicity of tiazofurin was headache, somnolence and nausea with no myelosuppression noted. By contrast, BR showed skeletal muscle toxicity, hepatotoxicity and myelosuppression in preclinical data. Skeletal muscle toxicity was noted in the paraspinal muscles and may represent dose-limiting toxicity. Since BR does exhibit myelosuppression, the most common chemotherapy-related side effect in humans, careful judgment is warranted should BR be included in multidrug regimens, although BR's potent cytotoxicity to tumor cells in preclinical models still makes it a promising drug.

AB - Benzamide riboside (BR), a synthetic C-nucleoside, acts as a strong growth inhibitor of cancer cells in vitro and in vivo. BR, like TR and related nucleoside prodrugs, act by anabolism to NAD analogs. These analogs selectively inhibit IMPDH, leading to depletion of cellular GTP, growth cessation, and cell differentiation. To date only preclinical studies have been carried out. However, in tiazofurin (TR), a related drug, phase I/II clinical trials have been conducted in patients with acute leukemia and shown to be a very promising agent with a response rate of 85% in 26 patients in one of the trials. Tiazofurin is now undergoing phase III clinical trials as a result. Dose limiting toxicity of tiazofurin was headache, somnolence and nausea with no myelosuppression noted. By contrast, BR showed skeletal muscle toxicity, hepatotoxicity and myelosuppression in preclinical data. Skeletal muscle toxicity was noted in the paraspinal muscles and may represent dose-limiting toxicity. Since BR does exhibit myelosuppression, the most common chemotherapy-related side effect in humans, careful judgment is warranted should BR be included in multidrug regimens, although BR's potent cytotoxicity to tumor cells in preclinical models still makes it a promising drug.

KW - Apoptosis

KW - Benzamide riboside

KW - Cancer chemotherapy

KW - Preclinical evaluation

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0036254114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036254114&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 787

EP - 792

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 7

ER -